1. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome.
- Author
-
Han, Velda X, Mohammad, Shekeeb S, Jones, Hannah F, Bandodkar, Sushil, Crow, Yanick J, Dale, Russell C, Sharpe, Cynthia, Sinclair, Adriane, Sinclair, Kate, Srinivasan, Deepa, Troedson, Christopher, Wong, Melanie, and Chaitow, Jeffrey
- Subjects
CEREBROSPINAL fluid ,NEOPTERIN ,BIOMARKERS ,CELL communication ,NEUROLOGICAL disorders - Abstract
Janus kinase (JAK) 1 inhibition represents a precision medicine approach in the treatment of Aicardi–Goutières syndrome (AGS), through targeting of type I interferon‐mediated cell signalling. Blood interferon mRNAseq has been proposed as a biomarker of disease with utility in therapeutic monitoring. Objective cerebrospinal fluid (CSF) biomarkers tracking treatment efficacy are currently lacking. Here, we report a retrospective case series of 13 patients (median age 6y, range 2y 6mo–17y; five females, eight males) with AGS demonstrating significantly elevated CSF neopterin levels at first sampling (median 200nmol/L, range 45–2024nmol/L), compared to 13 age‐matched controls with non‐inflammatory neurological conditions (median 23nmol/L, range 5–34nmol/L, p<0.001). Five patients with AGS treated with JAK inhibitors demonstrated a median 81.5% reduction of CSF neopterin (range –36% to –88% change from baseline), compared to eight untreated patients with AGS demonstrating a median 7% reduction in CSF neopterin (range –63% to +117% change) (p=0.047). Our data indicate a biological effect of JAK inhibitors, and the potential role of CSF neopterin as a biomarker of treatment response. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF